{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:46:36Z","timestamp":1782798396715,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00259-024-06610-3","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T02:02:26Z","timestamp":1705888946000},"page":"1582-1592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics"],"prefix":"10.1007","volume":"51","author":[{"given":"Hongzhang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-8301","authenticated-orcid":false,"given":"Xianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-159X","authenticated-orcid":false,"given":"Zhide","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"6610_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20:75\u20136.","journal-title":"Nat Rev Immunol"},{"key":"6610_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","volume":"17","author":"W Xu","year":"2020","unstructured":"Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17:137\u201350.","journal-title":"Nat Rev Urol"},{"key":"6610_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"6610_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24\u201333.","journal-title":"Trends Mol Med"},{"key":"6610_CR5","first-page":"17","volume":"350","author":"HT Jin","year":"2011","unstructured":"Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17\u201337.","journal-title":"Curr Top Microbiol Immunol"},{"key":"6610_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359\u201370.","journal-title":"Mol Cell"},{"key":"6610_CR7","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, et al. PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234:1313\u201325.","journal-title":"J Cell Physiol"},{"key":"6610_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","volume":"14","author":"M Nishino","year":"2017","unstructured":"Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655\u201368.","journal-title":"Nat Rev Clin Oncol"},{"key":"6610_CR9","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41374-020-0424-5","volume":"100","author":"S Gupta","year":"2020","unstructured":"Gupta S, Zugazagoitia J, Martinez-Morilla S, et al. Digital quantitative assessment of PD-L1 using digital spatial profiling. Lab Invest. 2020;100:1311\u20137.","journal-title":"Lab Invest"},{"key":"6610_CR10","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.7150\/thno.24762","volume":"8","author":"K Broos","year":"2018","unstructured":"Broos K, Lecocq Q, Raes G, et al. Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics. 2018;8:3559\u201370.","journal-title":"Theranostics"},{"key":"6610_CR11","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"6610_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2967\/jnumed.119.237891","volume":"61","author":"S L\u00fctje","year":"2020","unstructured":"L\u00fctje S, Feldmann G, Essler M, et al. Immune checkpoint imaging in oncology: a game changer toward personalized immunotherapy? J Nucl Med. 2020;61:1137\u201344.","journal-title":"J Nucl Med"},{"key":"6610_CR13","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.7150\/thno.38339","volume":"10","author":"PP van de Donk","year":"2020","unstructured":"van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, et al. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics. 2020;10:1708\u201318.","journal-title":"Theranostics"},{"key":"6610_CR14","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a noninvasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138.","journal-title":"Nat Med"},{"key":"6610_CR15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s00259-019-04646-4","volume":"47","author":"C Christensen","year":"2020","unstructured":"Christensen C, Kristensen LK, Alfsen MZ, et al. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. Eur J Nucl Med Mol Imaging. 2020;47:1302\u201313.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6610_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2967\/jnumed.120.250720","volume":"62","author":"KH Jung","year":"2021","unstructured":"Jung KH, Park JW, Lee JH, et al. 89Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy induced modulation of tumor PD-L1 expression. J Nucl Med. 2021;62:656\u201364.","journal-title":"J Nucl Med"},{"key":"6610_CR17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2967\/jnumed.119.240895","volume":"61","author":"MC Huisman","year":"2020","unstructured":"Huisman MC, Niemeijer AN, Windhorst AD, et al. Quantification of PD-L1 expression with 18F-BMS-986192 PET\/CT in patients with advanced-stage non-small cell lung cancer. J Nucl Med. 2020;61:1455\u201360.","journal-title":"J Nucl Med"},{"key":"6610_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2967\/jnumed.121.262368","volume":"63","author":"PH Nienhuis","year":"2022","unstructured":"Nienhuis PH, Antunes IF, Glaudemans A, et al. 18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors: a pilot study. J Nucl Med. 2021. J Nucl Med. 2022;63:899\u2013905.","journal-title":"J Nucl Med"},{"key":"6610_CR19","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1021\/acs.molpharmaceut.8b00399","volume":"15","author":"RA De Silva","year":"2018","unstructured":"De Silva RA, Kumar D, Lisok A, et al. Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer. Mol Pharm. 2018;15:3946\u201352.","journal-title":"Mol Pharm"},{"key":"6610_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107982118","volume":"118","author":"D Kumar","year":"2021","unstructured":"Kumar D, Mishra A, Lisok A, et al. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci USA. 2021;118: e2107982118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6610_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.121.262045","volume":"63","author":"X Zhou","year":"2022","unstructured":"Zhou X, Jiang J, Yang X, et al. First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. J Nucl Med. 2022;63:536\u201342.","journal-title":"J Nucl Med"},{"key":"6610_CR22","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1007\/s00259-022-05876-9","volume":"49","author":"M Zhou","year":"2022","unstructured":"Zhou M, Wang X, Chen B, et al. Preclinical and first-in-human evaluation of F-labeled D-peptide antagonist for PD-L1 status imaging with PET. Eur J Nucl Med Mol Imaging. 2022;49:4312\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6610_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119813","volume":"282","author":"A Awadasseid","year":"2021","unstructured":"Awadasseid A, Wu Y, Zhang W. Advance investigation on synthetic small-molecule inhibitors targeting PD-1\/PD-L1 signaling pathway. Life Sci. 2021;282: 119813.","journal-title":"Life Sci"},{"key":"6610_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejmech.2018.10.044","volume":"161","author":"T Chen","year":"2019","unstructured":"Chen T, Li Q, Liu Z, et al. Peptide-based and small synthetic molecule inhibitors on PD-1\/PD-L1 pathway: a new choice for immunotherapy? Eur J Med Chem. 2019;161:378\u201398.","journal-title":"Eur J Med Chem"},{"key":"6610_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1172\/JCI122216","volume":"129","author":"D Kumar","year":"2019","unstructured":"Kumar D, Lisok A, Dahmane E, et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest. 2019;129:616\u201330.","journal-title":"J Clin Invest"},{"key":"6610_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/ph16071051","volume":"16","author":"K Bamminger","year":"2023","unstructured":"Bamminger K, Pichler V, Vraka C, et al. On the road towards small-molecule programmed cell death 1 ligand 1 positron emission tomography tracers: a ligand-based drug design approach. Pharmaceuticals (Basel). 2023;16:1051\u201370.","journal-title":"Pharmaceuticals (Basel)"},{"key":"6610_CR27","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.1021\/acs.jmedchem.1c02162","volume":"65","author":"L Meng","year":"2022","unstructured":"Meng L, Fang J, Zhao L, et al. Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting the fibroblast activation protein. J Med Chem. 2022;65:8245\u201357.","journal-title":"J Med Chem"},{"key":"6610_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin A, Wei T, Meng H, et al. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019;18:139\u201347.","journal-title":"Mol Cancer"},{"key":"6610_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275\u201387.","journal-title":"Nat Rev Cancer"},{"key":"6610_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/modpathol.2016.186","volume":"30","author":"JA Rehman","year":"2017","unstructured":"Rehman JA, Han G, Carvajal-Hausdorf DE, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol. 2017;30:340\u20139.","journal-title":"Mod Pathol"},{"key":"6610_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00262-020-02818-y","volume":"70","author":"Q Liu","year":"2021","unstructured":"Liu Q, Jiang L, Li K, Li H, Lv G, Lin J, Qiu L. Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers. Cancer Immunol Immunother. 2021;70:1721\u201333.","journal-title":"Cancer Immunol Immunother"},{"key":"6610_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.nucmedbio.2020.05.006","volume":"86\u201387","author":"X Wen","year":"2020","unstructured":"Wen X, Shi C, Zhao L, et al. Immuno-SPECT\/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma. Nucl Med Biol. 2020;86\u201387:44\u201351.","journal-title":"Nucl Med Biol"},{"key":"6610_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2967\/jnumed.117.193268","volume":"58","author":"JR Nedrow","year":"2017","unstructured":"Nedrow JR, Josefsson A, Park S, et al. Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. J Nucl Med. 2017;58:1560\u20136.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06610-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T06:05:49Z","timestamp":1713938749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06610-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6610"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06610-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the Institutional Animal Care and Use Committee of Laboratory Animals Center for Xiamen University. And the protocols were prepared before the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}